In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Immutep Limited (IMMP), with a price target of $7. The company’s shares closed on Friday at $3.22.
McCarthy commented:
“Immutep presented data from its P1 TACTI-mel study at this year’s Society for Immunotherapy of Cancer (SITC) conference, highlighting the combination of eftilagimod (soluble LAG-3) with Merck’s (MRK – NR) anti-PD1, Keytruda in metastatic melanoma.”
According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 4.8% and a 37.8% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
Currently, the analyst consensus on Immutep Limited is a Moderate Buy with an average price target of $7.
See today’s analyst top recommended stocks >>
The company has a one-year high of $4.21 and a one-year low of $1.25. Currently, Immutep Limited has an average volume of 146.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Immutep Ltd. is a biotechnology company, which engages in developing immunotherapeutic treatments for cancer and autoimmune diseases. Its lead product is IMP321, which involves in clinical development for the treatment of breast cancer and melanoma. The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.
